Astellas
Life Sciences Radar, October 2026 edition. Evidence published up to 5 October 2026; job sites read on 6 October 2026. This brief covers AI in drug discovery, and research labs and data. Every link opens the public source. The brief covers the whole Astellas Pharma group, including the Cellafa Bioscience joint venture and its venture arm, Astellas Venture Management.
Disclosure: Andrew Wyatt, Ortent's principal, was Chief Growth Officer at Sapio Sciences, a lab software company, until April 2026. He has no current relationship with, or financial interest in, Sapio or any other supplier. Software vendors, including Sapio and its competitors, appear in this brief only where public sources name them.
Status: Ortent has reviewed this brief; it has not been independently validated. It sets out what the company and others have published. Search coverage varies by company and is described under Coverage limits, and a count of zero means none was identified, not that nothing happened. It does not predict buying intent or measure operational maturity. For this radar, process and CMC development are grouped with manufacturing and excluded from research labs and data.
Scores
| Theme | Priority (1 to 10) | Delivery (0 to 10) | Stage | Commitments made public, last 12 months | R&D roles open on 6 Oct 2026 |
|---|---|---|---|---|---|
| AI in drug discovery | 6 | 7 | live | 1 | 2 |
| Research labs and data | 5 | 4 | live | 1 | 1 |
The scores rest only on what the company itself has published about each theme. Commitments and open roles are observed activity: they show what is being started or staffed now, and they never change a score.
Summary
Astellas says AI has been part of its drug discovery since 2019 and shows it running: its Human-in-the-Loop platform combines AI design with robotic synthesis and testing, and it uses NVIDIA-powered supercomputing for small-molecule design. AI in drug discovery scores 6 out of 10 for priority and 7 for delivery. Research labs and data scores 5 for priority and 4 for delivery, backed by robotic synthesis and assay systems and in-house databases for each modality. The only commitment made public in the last 12 months is an AI-enabled Protein Station for biologics research automation, announced at the March 2026 R&D Day and counted under both themes; we identified none in the year before. On 6 October 2026 it had 2 open R&D roles in AI in drug discovery, including a computational chemistry lead, and 1 in research labs and data.
AI in drug discovery
What the company says: Priority 6
A key partnership is our participation in Tokyo-1 ... This initiative utilizes the Tokyo-1 GPU supercomputer to accelerate our research in molecular simulation and AI-based molecular design
Integrated Report 2025 (FY2024, English), 31 Oct 2025, p. 62
in drug discovery research, we aim to accelerate the development of biopharmaceuticals and improve productivity, not only through NVIDIA's AI-powered supercomputing for small molecule drug design that has already been implemented
Astellas R&D Day event transcript, 31 March 2026, 31 Mar 2026, p. 19
Strategic investments in AI will help us improve speed, quality and ... decision-making across R&D ... Research ... Human-in-the-Loop platform, an AI ... and robotics integrated system to optimize drug candidates ... NVIDIA-powered supercomputing to ... dramatically accelerate early-stage ... drug discovery
Astellas R&D Day presentation, 31 March 2026, 31 Mar 2026, p. 21
AI-driven gene therapy will lead to precise organ targeting, reduced toxicity, and enhanced treatment
Astellas R&D Day event transcript, 31 March 2026, 31 Mar 2026, p. 19
three Enterprise Priorities*1 - Growth Strategy, BOLD Ambition, and Sustainable Margin ... We are pioneering AI in R&D to advance our BOLD Ambition with digital capabilities that will accelerate innovation and improve success rates, from ... target identification
Integrated Report 2025 (FY2024, English), 31 Oct 2025, p. 59
Embed AI and data-driven insights across R&D to enable better decisions and higher productivity
CSP2026 presentation (Corporate Strategic Plan FY2026-FY2030), 26 May 2026, p. 13
We have fundamentally transformed our R&D ... organization and operating model ... Successfully building global, end-to-end ... capabilities across our transformed R&D ... Increasing R&D productivity through a ... disciplined, quality-driven framework ... Accelerating and enriching the pipeline by ... focusing on...
Astellas R&D Day presentation, 31 March 2026, 31 Mar 2026, p. 39
AIの活用による創薬力の強化
[Ortent translation: Strengthening our drug discovery capability through the use of AI]
Astellas newsletter No. 124 (individual-investor newsletter, Japanese), 31 Oct 2025, p. 1
What it shows running: Delivery 7, live
It also includes automated synthesis and assay systems using robots, and tools ... for automatically creating structure-activity relationship (SAR) tables ... The platform also ... incorporates the ability to remotely monitor the operation of the robots
Integrated Report 2025 (FY2024, English), 31 Oct 2025, p. 61
Astellas has been ahead of the curve, integrating AI into its drug development processes since 2019. The company's innovative "Human-in-the-Loop" platform is central to this effort
Integrated Report 2025 (English), 31 Oct 2025, p. 61
in drug discovery research, we aim to accelerate the development of biopharmaceuticals and improve productivity, not only through NVIDIA's AI-powered supercomputing for small molecule drug design that has already been implemented
Astellas R&D Day event transcript, 31 March 2026, 31 Mar 2026, p. 19
We use AI a lot for parts of drug discovery. We have been able to do something great in combination ... with robotics
Sustainability Meeting 2025 event transcript, 26 February 2026, 26 Feb 2026, p. 27
Today, AI is employed across most of our projects and by the majority of our researchers
Integrated Report 2025 (FY2024, English), 31 Oct 2025, p. 62
reducing the time required to advance an initial hit compound to a viable ... drug candidate by approximately 70% compared to conventional methods ... The research period was completed in just seven months—a 70% reduction ... from the previous average of two years
Integrated Report 2025 (FY2024, English), 31 Oct 2025, p. 61
by integrating Astellas’ proprietary ... simulation methods with the supercomputer Tokyo-1 and generative AI, we can ... accelerate the 3D structural prediction of compounds by more than 50-fold
Integrated Report 2025 (FY2024, English), 31 Oct 2025, p. 57
Through this collaboration, Astellas has already confirmed substantial improvements in computational speed across multiple projects and has successfully developed proprietary AI models
Integrated Report 2025 (FY2024, English), 31 Oct 2025, p. 62
The resulting drug candidate ... demonstrated a nearly ten-fold improvement in pharmacological activity over ... the lead compound
Integrated Report 2025 (FY2024, English), 31 Oct 2025, p. 61
Commitments made public in the last 12 months: 1
- AI-enabled Protein Station for biologics discovery automation: R&D Day: introducing an AI-enabled protein station for research automation to speed biologics discovery. New, announced, 31 Mar 2026. Published by: company.
Commitments made public in the year before: 0
None identified in the reviewed sources.
Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.
R&D roles open on 6 October 2026: 2
- Computational Chemistry Lead, Cambridge, MA, USA
- Scientist II, Antibody Engineering, CA, South San Francisco
These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.
Research labs and data
What the company says: Priority 5
A key initiative at Astellas is to enhance our global data infrastructure and governance to enable further AI adoption
Integrated Report 2025 (FY2024, English), 31 Oct 2025, p. 62
by actively promoting the use of data, including the proactive utilization of real-world data, integration of R&D database, and AI-driven simulation and modeling, we are working to speed up
Astellas R&D Day event transcript, 31 March 2026, 31 Mar 2026, p. 17
but also by introducing AI-enabled protein station for research automation
Astellas R&D Day event transcript, 31 March 2026, 31 Mar 2026, p. 19
Strategic investments in AI will help us improve speed, quality and ... Research ... AI-enabled Protein Station to Increase ... the speed and productivity of biologics ... discovery
Astellas R&D Day presentation, 31 March 2026, 31 Mar 2026, p. 21
R&D Productivity | Create and deliver greater VALUE faster ... Embedding Data-Driven Decision Making ... Embed AI and data-driven insights across R&D to enable better decisions and higher productivity
Corporate Strategic Plan 2026 (CSP2026) presentation, 26 May 2026, 26 May 2026, p. 13
We have fundamentally transformed our R&D ... organization and operating model ... Successfully building global, end-to-end ... capabilities across our transformed R&D ... Increasing R&D productivity through a ... disciplined, quality-driven framework ... Accelerating and enriching the pipeline by ... focusing on...
Astellas R&D Day presentation, 31 March 2026, 31 Mar 2026, p. 39
What it shows running: Delivery 4, live
It also includes automated synthesis and assay systems using robots, and tools ... for automatically creating structure-activity relationship (SAR) tables ... The platform also ... incorporates the ability to remotely monitor the operation of the robots
Integrated Report 2025 (FY2024, English), 31 Oct 2025, p. 61
we are building and enhancing ... dedicated in-house databases for each modality. Furthermore, the deployment ... of robotic technology to our overseas and joint research facilities is progressing, ... creating a global network to collect more uniform, high-quality data
Integrated Report 2025 (FY2024, English), 31 Oct 2025, p. 62
but also by introducing AI-enabled protein station for research automation
Astellas R&D Day event transcript, 31 March 2026, 31 Mar 2026, p. 19
Commitments made public in the last 12 months: 1
- AI-enabled Protein Station for biologics discovery automation: R&D Day: introducing an AI-enabled protein station for research automation to speed biologics discovery. New, announced, 31 Mar 2026. Published by: company.
Commitments made public in the year before: 0
None identified in the reviewed sources.
Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.
R&D roles open on 6 October 2026: 1
- Senior Research Associate, MA, Westborough
These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.
Technology named in these postings
Named as in use: Illumina sequencing platforms, Oxford Nanopore sequencing platforms.
A product named in a job advert shows what a team wants people to know. It is not proof of a purchase or an installed system.
Two questions to investigate (Ortent's interpretation)
- Lab robotics and lab data for research sit in several places, including research units rolling robots out to overseas sites and the new Protein Station. The Cellafa joint venture's Maholo platform serves cell therapy manufacturing and is outside this theme. Who decides on new robotic and data systems for research sites, and how does that decision relate to the robotics work done with Cellafa?
- AI discovery rests on the Human-in-the-Loop platform, NVIDIA supercomputing and outside partners, and in October 2025 the Chief Digital and Transformation Officer role was removed and digital moved into the Strategy function. Who now decides on AI discovery platforms, compute and computational contract research: the research units, the DigitalX team or Strategy, and how is it funded?
Coverage limits
Astellas's Japan recruitment site failed a secure connection check, so roles in Japan were not screened and are not in the open role counts. The FY2025 annual securities report could not be text-extracted and the Japanese Integrated Report 2025 lost its Japanese text, so no score rests on either. Business Wire and GlobeNewswire were not attempted, and Fierce Pharma, Fierce Biotech and BioSpectrum Asia blocked access, so some partner announcements may be missing. The press archive, results and R&D Day materials, consortium sources and the venture arm were searched in full.
Clarity when it counts.
For a board, advisory or fractional engagement, or a working call on the next stage, send a note. Thirty minutes is usually enough to test fit.
Request a 30-minute intro call